News Reunion Neuroscience files lawsuit against Mindset Pharma for copying drug compound The company is alleging that Mindset knowingly copied Reunion’s RE104 compound Natalia Buendia CalvilloMarch 17, 2023
Psychedelics Oklahoma assembly passes psychedelics research bill for Veteran PTSD The state's House of Representatives approved the legislation on Thursday Rowan DunneMarch 10, 2023
Psychedelics Optimi Health secures MDMA and psilocybin distribution agreement in Australia The company will supply Mind Medicine Australia with the substances, now considered designated therapies in the country Rowan DunneMarch 1, 2023
Psychedelics Awakn Life Sciences helps establish psychedelics clinics in Portugal Awakn will also be providing its clinical protocols and training to Portuguese clinicians in a 10-year agreement Rowan DunneFebruary 22, 2023
News Numinus expands psychedelics research operations in Arizona This will be the company's fifth research clinic in the United States Natalia Buendia CalvilloFebruary 17, 2023
Psychedelics PharmAla Biotech signs agreement to sell clinical-grade MDMA in Australia Companies are running more MDMA and psilocybin trials after the Australian drug regulation changes Natalia Buendia CalvilloFebruary 14, 2023
Psychedelics Psyched Wellness formulates first commercial Amanita muscaria extract The cartoon-like toadstool is psychoactive, has medicinal properties and lives in a symbiotic relationship with certain trees Rowan DunneFebruary 9, 2023
Psychedelics Optimi Health submits clinical trial application after developing proprietary MDMA drug The drug will be used to help establish a safe supply for patients in Canada and Australia Rowan DunneFebruary 7, 2023
News Australia re-classifies MDMA and psilocybin to be prescribed as medicine Psychiatrists can now prescribe MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression Natalia Buendia CalvilloFebruary 3, 2023
Psychedelics Woke Pharma and Swinburne U partner for Australia’s biggest psilocybin trial The AUD$5M study will involve about 160 participants and aims to help combat treatment-resistant depression Rowan DunneFebruary 1, 2023